Crown Bioscience, a JSR Life Sciences company, is a global Contract Research Organization (CRO) partnering with biotech and pharmaceutical companies to rapidly advance the discovery and development of oncology drugs. As the exclusive preclinical CRO providing tumor organoid services with the well-established Hubrecht Organoid Technology, we offer over 600 organoid models spanning 22 cancer indications. Furthermore, we have developed the world’s largest commercially available PDX collection. Our focus on helping our customers develop novel therapies aims to ensure that patients receive the right treatment at the right time. Founded in 2006, we have 13 facilities across the US, Europe, and Asia.
Therapeutic Areas : At Crown Bioscience, we are driven by our mission to ensure that every patient gets the right treatment at the right time. That is why we are trusted by the world’s leading biopharmaceutical companies to advance their preclinical and translational research programs. With our extensive experience in the areas of oncology, immuno-oncology, and immune-mediated inflammatory diseases. Leverage the infinite possibilities of scientific innovation. Model Systems : With a comprehensive selection of models we are committed to advancing your preclinical development programs in a timely and cost-effective manner. Our more recent and novel in vitro organoid service offerings, are unmatched, and allow you to take advantage of the most translatable 3D in vitro models on the market. Technologies : Make better-informed decisions: ground in science, driven by data. At Crown Bioscience, we are constantly developing, evaluating, and utilizing innovative technologies, to serve the dynamic needs of your preclinical and translational studies. We provide end-to-end service to our customers, using the most advanced analysis and generate comprehensive data, utilizing machine intelligence to help you make better-informed decisions.